Rona Y. Sonabend, MD

Medical Director, Clinical Systems Integration Process Improvement, Texas Children’s Hospital

Dr. Sonabend’s philosophy towards healthcare is combining the science of medicine with the art of care delivery in a patient-centered quality driven manner.

Clinical Interests

Dr. Sonabend’s clinical interests include caring for children with neuro-endocrine dysfunctions with a specialized interest in endocrine complications secondary to treatment of childhood cancer.

When she’s not seeing patients, Rona Sonabend serves as the Medical Director of Clinical Systems Integration Process Improvement, which coordinates and prioritizes Quality Improvement and Safety initiatives focused on data, data analysis, clinical technology operations, information systems platforms and clinical standards at Texas Children’s Hospital. Her role includes supervision of nine complex disease-based care process teams throughout the institution while co-leading the Diabetes Care Process Team. She is also the Medical Director of Quality Improvement for the section of Pediatric Endocrinology.

Research Interests

Her current research explores the impact of radiation and chemotherapy on the neuroendocrine system in children with Acute Lymphoblastic Leukemia (ALL) and Central Nervous System tumors.

Speaker Sessions

27 – A Population Health Management Diabetes Case Study

Diabetes is a major chronic disease that affects individuals of all ages. It is the most common life-threatening, chronic illness for children living in developed countries. Texas Children’s Hospital, a leader in the research and treatment of children with diabetes, evaluates more than 2,500 cases annually with the goal of helping children, adolescents, and young adults to manage their illness effectively—and live long, healthy, and active lives.

Join Texas Children’s to learn how its data-driven approach to population health management for patients with diabetes coupled with the formation of Diabetes Care Process Teams (CPTs) is benefiting its patient population with improved outcomes including 44 percent relative decrease in length-of-stay for patients with diabetic ketoacidosis (DKA) and 30.9 percent relative reduction in recurrent DKA admissions per fiscal year.

Apply to be an Analytics Walkabout Speaker

  • This field is for validation purposes and should be left unchanged.